Microsatellite Stable Colorectal Cancer Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight

(Albany, USA) As per DelveInsight's assessment, globally, about 10+ key pharma and biotech companies are working on 10+ pipeline drugs in the Microsatellite Stable Colorectal Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Microsatellite Stable Colorectal Cancer Pipeline Insight, 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Microsatellite Stable Colorectal Cancer Therapeutics Market.

The report provides a detailed description of the Microsatellite Stable Colorectal Cancer drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Microsatellite Stable Colorectal Cancer Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/microsatellite-stable-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Microsatellite Stable Colorectal Cancer Pipeline Report:
• Microsatellite Stable Colorectal Cancer Companies across the globe are diligently working toward developing novel Microsatellite Stable Colorectal Cancer treatment therapies with a considerable amount of success over the years.
• Microsatellite Stable Colorectal Cancer Companies in the Therapeutics Market are Gritstone Oncology, Merck Sharp & Dohme Corp., Arrys Therapeutics, NeoImmuneTec, And Many Others
• Microsatellite Stable Colorectal Cancer Therapies Covered in the Report Include grapiprant, GRANITE, MK7123-034, NT-I7, TPST-149, Evorpacept, Nivolumab, Ipilimumab, and many others.
• Targeting CTLA-4: A Possible Solution for Microsatellite-Stable Colorectal Cancer: In this study, researchers explored a combination of chemotherapies and immunotherapies for MSS RAS mutant metastatic colorectal cancer. The trial involved using a combination of FOLFOX (a chemotherapy regimen), durvalumab (an anti-PD-L1 drug), and tremelimumab (an anti-CTLA-4 drug) as first-line treatment. The goal was to promote the recruitment and activation of the adaptive immune system at the tumor level, resulting in clinical benefit for a significant number of patients.
• Global Randomized Phase II Trial: A global randomized phase II trial for microsatellite-stable metastatic colorectal cancer is currently enrolling patients (ClinicalTrials.gov identifier NCT05608044). This trial aims to evaluate novel treatment approaches for MSS colorectal cancer.

Microsatellite Stable Colorectal Cancer Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Microsatellite Stable Colorectal Cancer therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Microsatellite Stable Colorectal Cancer treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Microsatellite Stable Colorectal Cancer drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Microsatellite Stable Colorectal Cancer treatment market.

Learn More about the Clinical and Commercial Development Activities in the Microsatellite Stable Colorectal Cancer Therapeutics Domain @
https://www.delveinsight.com/report-store/microsatellite-stable-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Microsatellite Stable Colorectal Cancer Therapeutics Analysis
There are approx. 10+ key companies which are developing the therapies for Microsatellite Stable Colorectal Cancer. Currently, Merck Sharp & Dohme Corp. is leading the therapeutics market with its Microsatellite Stable Colorectal Cancer drug candidates in the mid to advanced stage of clinical development.

Microsatellite Stable Colorectal Cancer Companies in the Therapeutics Market Include:
• Gritstone Oncology
• Merck Sharp & Dohme Corp.
• Arrys Therapeutics
• NeoImmuneTec
And Many Others

Emerging and Marketed Microsatellite Stable Colorectal Cancer Therapies Covered in the Report Include:
• GRANITE: Gritstone Oncology
• MK7123-034: Merck Sharp & Dohme Corp.
And Many More

Get an in-depth Assessment of the Emerging Therapies and Microsatellite Stable Colorectal Cancer Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/microsatellite-stable-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

The Report Covers the Emerging Microsatellite Stable Colorectal Cancer Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
Microsatellite Stable Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Subcutaneous
• Intravenous
• Oral
• Intramuscular

Molecule Type
Products have been categorized under various Molecule types such as
• Small molecules
• Natural metabolites
• Monoclonal antibodies

Request for Sample PDF to Understand More About the Microsatellite Stable Colorectal Cancer Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/microsatellite-stable-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Report Introduction
2. Executive Summary
3. Microsatellite Stable Colorectal Cancer Current Treatment Patterns
4. Microsatellite Stable Colorectal Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Microsatellite Stable Colorectal Cancer Late-Stage Products (Phase-III)
7. Microsatellite Stable Colorectal Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Microsatellite Stable Colorectal Cancer Discontinued Products
13. Microsatellite Stable Colorectal Cancer Product Profiles
14. Microsatellite Stable Colorectal Cancer Companies
15. Microsatellite Stable Colorectal Cancer Drugs
16. Dormant and Discontinued Products
17. Microsatellite Stable Colorectal Cancer Unmet Needs
18. Microsatellite Stable Colorectal Cancer Future Perspectives
19. Microsatellite Stable Colorectal Cancer Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/microsatellite-stable-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Reports:
• Pediatric Obesity Market: https://www.delveinsight.com/report-store/pediatric-obesity-market
• Pemphigus Vulgaris Market: https://www.delveinsight.com/report-store/pemphigus-vulgaris-market
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Radioligand Therapies Market: https://www.delveinsight.com/report-store/radioligand-therapies-market-forecast
• Refractory Angina Market: https://www.delveinsight.com/report-store/refractory-angina-market
• Severe Hypoglycemia Market: https://www.delveinsight.com/report-store/severe-hypoglycemia-market
• Tim-3-next Generation Immunotherapy Market: https://www.delveinsight.com/report-store/tim-3-next-generation-immunotherapy-competitive-landscape
• Trigeminal Neuralgia Market Size: https://www.delveinsight.com/report-store/trigeminal-neuralgia-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• Ventricular Hypertrophy Market: https://www.delveinsight.com/report-store/hypertrophic-cardiomyopathy-market
• Vitamin A Deficiency Market: https://www.delveinsight.com/report-store/vitamin-a-deficiency-market
• Wegener S Granulomatosis/granulomatosis With Polyangiitis Market: https://www.delveinsight.com/report-store/wegeners-granulomatosis-market
• X Linked Hypophosphatemia Market: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/primary-research-services
Case study: https://www.delveinsight.com/case-study/esmo-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.